TY - JOUR AU - Judson, I. AU - Bulusu, R. AU - Seddon, B. AU - Dangoor, A. AU - Wong, N. AU - Mudan, S. PY - 2017 DA - 2017// TI - UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST) JO - Clin Sarcoma Res. VL - 7 UR - https://doi.org/10.1186/s13569-017-0072-8 DO - 10.1186/s13569-017-0072-8 ID - Judson2017 ER - TY - JOUR AU - Starczewska Amelio, J. M. AU - Cid Ruzafa, J. AU - Desai, K. AU - Tzivelekis, S. AU - Muston, D. AU - Khalid, J. M. PY - 2014 DA - 2014// TI - Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model JO - BMC Cancer. VL - 14 UR - https://doi.org/10.1186/1471-2407-14-364 DO - 10.1186/1471-2407-14-364 ID - Starczewska Amelio2014 ER - TY - JOUR AU - Miettinen, M. AU - Lasota, J. PY - 2006 DA - 2006// TI - Gastrointestinal stromal tumors: pathology and prognosis at different sites JO - Semin Diagn Pathol VL - 23 UR - https://doi.org/10.1053/j.semdp.2006.09.001 DO - 10.1053/j.semdp.2006.09.001 ID - Miettinen2006 ER - TY - JOUR AU - Plaat, B. E. C. AU - Hollema, H. H. AU - Molenaar, W. M. AU - Torn Broers, G. H. AU - Pijpe, J. J. AU - Mastik, M. F. PY - 2000 DA - 2000// TI - Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.18.3211 DO - 10.1200/JCO.2000.18.18.3211 ID - Plaat2000 ER - TY - JOUR AU - Dematteo, R. P. AU - Heinrich, M. C. AU - El-Rifai, W. M. AU - Demetri, G. PY - 2002 DA - 2002// TI - Clinical management of gastrointestinal stromal tumors: before and after STI-571 JO - Hum Pathol VL - 33 UR - https://doi.org/10.1053/hupa.2002.124122 DO - 10.1053/hupa.2002.124122 ID - Dematteo2002 ER - TY - JOUR AU - Demetri, G. D. AU - Mehren, M. AU - Blanke, C. D. AU - Abbeele, A. D. AU - Eisenberg, B. AU - Roberts, P. J. PY - 2002 DA - 2002// TI - Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors JO - N Engl J Med. VL - 347 UR - https://doi.org/10.1056/NEJMoa020461 DO - 10.1056/NEJMoa020461 ID - Demetri2002 ER - TY - JOUR AU - Demetri, G. D. AU - Oosterom, A. T. AU - Garrett, C. R. AU - Blackstein, M. E. AU - Shah, M. H. AU - Verweij, J. PY - 2006 DA - 2006// TI - Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial JO - Lancet. VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69446-4 DO - 10.1016/S0140-6736(06)69446-4 ID - Demetri2006 ER - TY - JOUR AU - Demetri, G. D. AU - Reichardt, P. AU - Kang, Y. K. AU - Blay, J. Y. AU - Rutkowski, P. AU - Gelderblom, H. PY - 2013 DA - 2013// TI - Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial JO - Lancet. VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61857-1 DO - 10.1016/S0140-6736(12)61857-1 ID - Demetri2013 ER - TY - JOUR AU - Joensuu, H. AU - Eriksson, M. AU - Hall, K. S. AU - Hartmann, J. T. AU - Pink, D. AU - Schütte, J. PY - 2012 DA - 2012// TI - One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JO - JAMA VL - 307 UR - https://doi.org/10.1001/jama.2012.347 DO - 10.1001/jama.2012.347 ID - Joensuu2012 ER - TY - STD TI - ClinicalTrials.gov. Three versus five years of adjuvant imatinib as treatment of patients with operable GIST. U.S. Natl. Libr. Med. 2015 https://clinicaltrials.gov/ct2/show/NCT02413736. Accessed 11 June 2019. UR - https://clinicaltrials.gov/ct2/show/NCT02413736 ID - ref10 ER - TY - JOUR AU - Wilhelm, S. M. AU - Dumas, J. AU - Adnane, L. AU - Lynch, M. AU - Carter, C. A. AU - Schütz, G. PY - 2011 DA - 2011// TI - Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity JO - Int J Cancer. VL - 129 UR - https://doi.org/10.1002/ijc.25864 DO - 10.1002/ijc.25864 ID - Wilhelm2011 ER - TY - JOUR AU - Mross, K. AU - Frost, A. AU - Steinbild, S. AU - Hedbom, S. AU - Büchert, M. AU - Fasol, U. PY - 2012 DA - 2012// TI - A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors JO - Clin Cancer Res. VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1900 DO - 10.1158/1078-0432.CCR-11-1900 ID - Mross2012 ER - TY - JOUR AU - George, S. AU - Wang, Q. AU - Heinrich, M. C. AU - Corless, C. L. AU - Zhu, M. AU - Butrynski, J. E. PY - 2012 DA - 2012// TI - Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial JO - J Clin Oncol. VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.9394 DO - 10.1200/JCO.2011.39.9394 ID - George2012 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer. VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - National Institute of Cancer. Common terminology criteria for adverse events (CTCAE), Version 4.0, DCTD, CTI, NIH, DHHS. NIH Publ. 2009. ID - ref15 ER - TY - JOUR PY - 2010 DA - 2010// TI - Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients JO - J Clin Oncol. VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.2099 DO - 10.1200/JCO.2009.24.2099 ID - ref16 ER - TY - JOUR AU - Call, J. W. AU - Wang, Y. AU - Montoya, D. AU - Scherzer, N. J. AU - Heinrich, M. C. PY - 2019 DA - 2019// TI - Correction to: survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry JO - Clin Sarcoma Res. VL - 9 UR - https://doi.org/10.1186/s13569-019-0117-2 DO - 10.1186/s13569-019-0117-2 ID - Call2019 ER - TY - JOUR AU - Heinrich, M. C. AU - Jones, R. L. AU - Mehren, M. AU - Bauer, S. AU - Kang, Y. -. K. AU - Schoffski, P. PY - 2019 DA - 2019// TI - Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST) JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.11022 DO - 10.1200/JCO.2019.37.15_suppl.11022 ID - Heinrich2019 ER - TY - JOUR AU - Bauer, S. AU - George, S. AU - Kang, Y. -. K. AU - Tap, W. D. AU - Zhou, T. AU - Picazio, N. PY - 2018 DA - 2018// TI - 1662TiPVOYAGER: an open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST) JO - Ann Oncol. VL - 29 ID - Bauer2018 ER - TY - STD TI - ClinicalTrials.gov. Phase 3 study of DCC-2618 vs placebo in advanced gist patients who have been treated with prior anticancer therapies (invictus). U.S. Natl. Libr. Med. 2017. https://clinicaltrials.gov/ct2/show/NCT03353753. Accessed 21 May 2019. UR - https://clinicaltrials.gov/ct2/show/NCT03353753 ID - ref20 ER - TY - STD TI - ClinicalTrials.gov. A study of DCC-2618 vs sunitinib in advanced GIST patients after treatment with imatinib (intrigue). U.S. Natl. Libr. Med. 2018. https://clinicaltrials.gov/ct2/show/NCT03673501. Accessed 21 May 2019. UR - https://clinicaltrials.gov/ct2/show/NCT03673501 ID - ref21 ER - TY - JOUR AU - Mir, O. AU - Cropet, C. AU - Toulmonde, M. AU - Le Cesne, A. AU - Molimard, M. AU - Bompas, E. PY - 2016 DA - 2016// TI - Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00075-9 DO - 10.1016/S1470-2045(16)00075-9 ID - Mir2016 ER - TY - JOUR AU - Reichardt, P. AU - Blay, J. Y. AU - Gelderblom, H. AU - Schlemmer, M. AU - Demetri, G. D. AU - Bui-nguyen, B. PY - 2012 DA - 2012// TI - Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib JO - Ann Oncol. VL - 23 UR - https://doi.org/10.1093/annonc/mdr598 DO - 10.1093/annonc/mdr598 ID - Reichardt2012 ER - TY - JOUR AU - Mir, O. AU - Brodowicz, T. AU - Italiano, A. AU - Wallet, J. AU - Blay, J. Y. AU - Bertucci, F. PY - 2016 DA - 2016// TI - Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30507-1 DO - 10.1016/S1470-2045(16)30507-1 ID - Mir2016 ER - TY - JOUR AU - Krishnamoorthy, S. K. AU - Relias, V. AU - Sebastian, S. AU - Jayaraman, V. AU - Saif, M. W. PY - 2015 DA - 2015// TI - Management of regorafenib-related toxicities: a review JO - Therap Adv Gastroenterol. VL - 8 UR - https://doi.org/10.1177/1756283X15580743 DO - 10.1177/1756283X15580743 ID - Krishnamoorthy2015 ER - TY - JOUR AU - Tetzlaff, E. D. AU - Davey, M. P. PY - 2013 DA - 2013// TI - Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor JO - J Adv Pract Oncol. VL - 4 ID - Tetzlaff2013 ER - TY - JOUR AU - Choi, H. AU - Charnsangavej, C. AU - Faria, S. C. AU - Macapinlac, H. A. AU - Burgess, M. A. AU - Patel, S. R. PY - 2007 DA - 2007// TI - Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria JO - J Clin Oncol. VL - 25 UR - https://doi.org/10.1200/JCO.2006.07.3049 DO - 10.1200/JCO.2006.07.3049 ID - Choi2007 ER - TY - JOUR AU - Schvartsman, G. AU - Wagner, M. J. AU - Amini, B. AU - Zobniw, C. M. AU - Trinh, V. A. AU - Barbo, A. G. PY - 2017 DA - 2017// TI - Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients JO - Sci Rep. VL - 7 UR - https://doi.org/10.1038/s41598-017-09132-1 DO - 10.1038/s41598-017-09132-1 ID - Schvartsman2017 ER - TY - JOUR AU - Bekaii-Saab, T. AU - Ou, F. -. S. AU - Ahn, D. AU - Boland, P. AU - Ciombor, K. AU - Heying, E. PY - 2019 DA - 2019// TI - Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study JO - Lancet Oncol. VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30272-4 DO - 10.1016/S1470-2045(19)30272-4 ID - Bekaii-Saab2019 ER -